HomeBUSINESS
BUSINESS

Mundipharma to Enter Japanese Anesthesia Market with Remimazolam Licensed from German Company
(Dec.20.2017)

Mundipharma has announced that it has entered into an exclusive license agreement with Germany-based Paion AG to develop and commercialize the partner’s investigational anesthetic remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic agent, in Japan. This is Mundipharma’s first product in the Japanese anesthesia market, and a clinical development program for general anesthesia has already been completed in Japan ...
(LOG IN FOR FULL STORY)